News

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Detailed price information for Xoma Royalty Corporation (XOMA-Q) from The Globe and Mail including charting and trades.
Medical Marketing & Media3d
Rx Rundown: Pfizer, SERB Pharmaceuticals, Novo Nordisk and more
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
The Malaysian Reserve3d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of ...
I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals
Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...
The Pharma Letter6d
Promise of gamma delta bispecific antibodies prompts XOMA acquisition
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.
Precision Medicine Online6d
Xoma Royalty to Acquire Lava Therapeutics, End Development of Lead Candidate
The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.
Xoma strikes deals to buy struggling biotechs HilleVax, Lava
The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...